Lasmiditan and Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Tablets
Determining the interaction of Lasmiditan and Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Tablets and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration with lasmiditan may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) transporters. The proposed mechanism, based on in vitro data, involves decreased clearance due to inhibition of P-gp and BCRP by lasmiditan. The clinical relevance is unknown. MANAGEMENT: Concomitant use of lasmiditan with drugs that are P-gp and/or BCRP substrates should be avoided when possible. If coadministration is required, patients should be carefully monitored for increased adverse reactions of these drugs and dosing adjusted as necessary. References "Product Information. Reyvow (lasmiditan)." Lilly, Eli and Company, Indianapolis, IN.
Professional:GENERALLY AVOID: Coadministration with lasmiditan may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) transporters. The proposed mechanism, based on in vitro data, involves decreased clearance due to inhibition of P-gp and BCRP by lasmiditan. The clinical relevance is unknown.
MANAGEMENT: Concomitant use of lasmiditan with drugs that are P-gp and/or BCRP substrates should be avoided when possible. If coadministration is required, patients should be carefully monitored for increased adverse reactions of these drugs and dosing adjusted as necessary.
- "Product Information. Reyvow (lasmiditan)." Lilly, Eli and Company, Indianapolis, IN.
Generic Name: dasabuvir / ombitasvir / paritaprevir / ritonavir
Brand name: Viekira XR, Viekira Pak
Synonyms: Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets, and Dasabuvir
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Lasmiditan-Omeclamox-Pak
- Lasmiditan-Omega-3 Fatty Acid Capsules
- Lasmiditan-Omega-3 Fatty Acids
- Lasmiditan-Omega-3 polyunsaturated fatty acids
- Lasmiditan-Omega-3-acid ethyl esters
- Lasmiditan-Omega-3-carboxylic acids
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Tablets-Latanoprost
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Tablets-Latanoprost and netarsudil ophthalmic
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Tablets-Latanoprost and Timolol
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Tablets-Latanoprost Eye Drops (Emulsion)
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Tablets-Latanoprost Eye Drops (Solution)
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Tablets-Latanoprost ophthalmic